Related Experiment Videos
Lectin and serum-PSA interaction as a screening test for prostate cancer
Pranab S Basu1, Ramdhan Majhi, Sandip K Batabyal
1Indian Institute of Chemical Biology 4, Raja S.C. Mullick Road, Jadavpur, 700032 Calcutta, India. pranabbasu@iicb.res.in
Clinical Biochemistry
|July 10, 2003
Summary
Distinguishing prostate cancer from benign conditions is possible using lectin-prostate specific antigen (PSA) binding. Lower carbohydrate content in Concanavalin A-PSA complexes suggests prostate cancer, aiding in biopsy decisions.
Area of Science:
- Biochemistry
- Oncology
- Urology
Background:
- Prostate cancer and benign prostate hyperplasia share common biomarkers, complicating differential diagnosis.
- Prostate-specific antigen (PSA) is a key biomarker, but its glycosylation patterns may differ between cancerous and benign conditions.
Purpose of the Study:
- To differentiate prostate cancer from benign prostate hyperplasia using lectin-PSA binding.
- To investigate the utility of Concanavalin A (Con A) and serum PSA interaction for diagnosing prostate cancer.
Main Methods:
- Employed the quantitative precipitin method to analyze Concanavalin A-carbohydrate interactions.
- Studied serum PSA from patients diagnosed with prostate cancer and benign prostate hyperplasia.
Main Results:
- Significantly lower carbohydrate content was observed in the Concanavalin A-PSA precipitate from prostate cancer patients compared to those with benign prostate hyperplasia.
- This reduction in carbohydrate content may indicate altered glycosylation or sugar chain structure of PSA in prostate cancer.
Conclusions:
- A serum carbohydrate content threshold of <3.0 microg/ml in the Concanavalin A-PSA precipitate strongly suggests prostate cancer.
- This cutoff level can effectively reduce unnecessary biopsies in men with total PSA levels between 4.0 and 10.0 ng/ml.